Gypsyamber Dʼsouza1, Thomas E Carey, William N William, Minh Ly Nguyen, Eric C Ko, James Riddell, Sara I Pai, Vishal Gupta, Heather M Walline, J Jack Lee, Gregory T Wolf, Dong M Shin, Jennifer R Grandis, Robert L Ferris. 1. *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; †Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, MI; ‡Department of Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX; §Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA; ‖Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY; ¶Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI; #Department of Otolaryngology/Head and Neck Surgery, Johns Hopkins University, Baltimore, MD; **Cancer Biology Program, University of Michigan, Ann Arbor, MI; ††Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, TX; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA; and ‖‖Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
BACKGROUND: HIV-infected individuals have a higher incidence of head and neck cancer (HNC). METHODS: Case series of 94 HIV-infected HNC patients (HIV-HNC) at 6 tertiary care referral centers in the US between 1991 and 2011. Clinical and risk factor data were abstracted from the medical record. Risk factors for survival were analyzed using Cox proportional hazard models. Human papillomavirus (HPV) and p16 testing was performed in 46 tumors. Findings were compared with Surveillance Epidemiology and End Results HNC (US-HNC) data. RESULTS: This study represents the largest HIV-HNC series reported to date. HIV-HNC cases were more likely than US-HNC to be male (91% vs. 68%), younger (median age, 50 vs. 62 years), nonwhite (49% vs. 18%), and current smokers (61% vs. 18%). Median HIV-HNC survival was not appreciably lower than US-HNC survival (63 vs. 61 months). At diagnosis, most cases were currently on highly active antiretroviral therapy (77%) but had detectable HIV viremia (99%), and median CD4 was 300 cells per microliter (interquartile range = 167-500). HPV was detected in 30% of HIV-HNC and 64% of HIV-oropharyngeal cases. Median survival was significantly lower among those with CD4 counts ≤200 than >200 cells per microliter at diagnosis (16.1 vs. 72.8 months, P < 0.001). In multivariate analysis, poorer survival was associated with CD4 <100 cells per microliter [adjusted hazard ratio (aHR) = 3.09, 95% confidence interval (CI): 1.15 to 8.30], larynx/hypopharynx site (aHR = 3.54, 95% CI: 1.34 to 9.35), and current tobacco use (aHR = 2.54, 95% CI: 0.96 to 6.76). CONCLUSIONS: Risk factors for the development of HNC in patients with HIV infection are similar to the general population, including both HPV-related and tobacco/alcohol-related HNC.
BACKGROUND:HIV-infected individuals have a higher incidence of head and neck cancer (HNC). METHODS: Case series of 94 HIV-infected HNCpatients (HIV-HNC) at 6 tertiary care referral centers in the US between 1991 and 2011. Clinical and risk factor data were abstracted from the medical record. Risk factors for survival were analyzed using Cox proportional hazard models. Human papillomavirus (HPV) and p16 testing was performed in 46 tumors. Findings were compared with Surveillance Epidemiology and End Results HNC (US-HNC) data. RESULTS: This study represents the largest HIV-HNC series reported to date. HIV-HNC cases were more likely than US-HNC to be male (91% vs. 68%), younger (median age, 50 vs. 62 years), nonwhite (49% vs. 18%), and current smokers (61% vs. 18%). Median HIV-HNC survival was not appreciably lower than US-HNC survival (63 vs. 61 months). At diagnosis, most cases were currently on highly active antiretroviral therapy (77%) but had detectable HIV viremia (99%), and median CD4 was 300 cells per microliter (interquartile range = 167-500). HPV was detected in 30% of HIV-HNC and 64% of HIV-oropharyngeal cases. Median survival was significantly lower among those with CD4 counts ≤200 than >200 cells per microliter at diagnosis (16.1 vs. 72.8 months, P < 0.001). In multivariate analysis, poorer survival was associated with CD4 <100 cells per microliter [adjusted hazard ratio (aHR) = 3.09, 95% confidence interval (CI): 1.15 to 8.30], larynx/hypopharynx site (aHR = 3.54, 95% CI: 1.34 to 9.35), and current tobacco use (aHR = 2.54, 95% CI: 0.96 to 6.76). CONCLUSIONS: Risk factors for the development of HNC in patients with HIV infection are similar to the general population, including both HPV-related and tobacco/alcohol-related HNC.
Authors: Michael S McLemore; Missak Haigentz; Richard V Smith; Gerard J Nuovo; Llucia Alos; Antonio Cardesa; Margaret Brandwein-Gensler Journal: Head Neck Pathol Date: 2010-03-24
Authors: Jennifer E Cameron; Donald Mercante; Megan O'Brien; Ann M Gaffga; Janet E Leigh; Paul L Fidel; Michael E Hagensee Journal: Sex Transm Dis Date: 2005-11 Impact factor: 2.830
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2010-05 Impact factor: 3.147
Authors: Eric A Engels; Robert J Biggar; H Irene Hall; Helene Cross; Allison Crutchfield; Jack L Finch; Rebecca Grigg; Tara Hylton; Karen S Pawlish; Timothy S McNeel; James J Goedert Journal: Int J Cancer Date: 2008-07-01 Impact factor: 7.396
Authors: Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen Journal: Clin Cancer Res Date: 2016-06-29 Impact factor: 12.531
Authors: D J Speicher; V Ramirez-Amador; D P Dittmer; J Webster-Cyriaque; M T Goodman; A-B Moscicki Journal: Oral Dis Date: 2016-04 Impact factor: 3.511
Authors: Sara I Pai; J Jack Lee; Thomas E Carey; William H Westra; Soldano Ferrone; Charles Moore; Marina B Mosunjac; Dong M Shin; Robert L Ferris Journal: Oral Oncol Date: 2017-12-28 Impact factor: 5.337
Authors: Heather M Walline; Thomas E Carey; Christine M Goudsmit; Emily L Bellile; Gypsyamber D'Souza; Lisa A Peterson; Jonathan B McHugh; Sara I Pai; J Jack Lee; Dong M Shin; Robert L Ferris Journal: Mol Cancer Res Date: 2016-11-29 Impact factor: 5.852
Authors: Hongzheng Zhang; Sungjin Kim; Zhengjia Chen; Sreenivas Nannapaneni; Amy Y Chen; Charles E Moore; Gabriel Sica; Marina Mosunjac; Minh Ly T Nguyen; Gypsyamber D'Souza; Thomas E Carey; Lisa A Peterson; Jonathan B McHugh; Martin Graham; Christine M Komarck; Gregory T Wolf; Heather M Walline; Emily Bellile; James Riddell; Sara I Pai; David Sidransky; William H Westra; William N William; J Jack Lee; Adel K El-Naggar; Robert L Ferris; Raja Seethala; Jennifer R Grandis; Zhuo Georgia Chen; Nabil F Saba; Dong M Shin Journal: Head Neck Date: 2017-09-25 Impact factor: 3.147
Authors: Cristina E Brickman; Kathleen J Propert; Jessica S Merlin; Jeffrey C Liu; Sequoya Eady; Amy Mcghee-Jez; Camille Ragin; Surbhi Grover; Roger B Cohen; Robert Gross Journal: AIDS Res Hum Retroviruses Date: 2019-08-29 Impact factor: 2.205
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455